Drug Target Review – Issue 3 2022 By Drug Target Review 14 September 2022 Shares 7 Share this post Share via Facebook Like Twitter Pinterest LinkedIn Digg Del Tumblr VKontakte Print Email Reddit Buffer Love This Weibo Pocket Xing Odnoklassniki WhatsApp Meneame Blogger Amazon Yahoo Mail Gmail AOL Newsvine HackerNews Evernote MySpace Mail.ru Viadeo Line Flipboard Comments Yummly SMS Viber Telegram Subscribe Skype Facebook Messenger Kakao LiveJournal Yammer Edgar Fintel Mix Instapaper Copy Link In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience. Included in this issue: SYNTHETIC BIOLOGY Synthetic biology is ready for the therapeutic limelight Dr Dan Mandell, GRO Biosciences TARGETS Insights into GPCRs via innovative imaging Dr Jonathan Javitch, Columbia University ANTIBODIES T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma? Dr Edmond Chan, Janssen COVID-19 In search of COVID-19 antibodies Ria Kakkad, Drug Target Review ASSAYS Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials Dr Rolland Carlson and Dr Richard Brandon, Immunexpress VACCINE DEVELOPMENT Advancing vaccines with extracellular vesicles Dr Christopher Locher, Versatope Therapeutics NEUROSCIENCE Right model, right complexity: using in vitro human disease cell models in drug discovery Dr Beth Hoffman, Origami Therapeutics